Chemotherapy for Lung Cancer in the Era of Personalized Medicine
Seung Hyeun Lee
Tuberc Respir Dis. 2019;82(3):179-189.   Published online 2018 Dec 20     DOI:
Citations to this article as recorded by Crossref logo
A review on non-small cell lung cancer
Sunil Kumar Verma, Minakshi Pandey, Renu Khare, Devendra Singh
Vacunas.2024; 25(2): 239.     CrossRef
Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer
Ling-bing Li, Ling-xiao Yang, Lei Liu, Fan-rong Liu, Alex H. Li, Yi-lin Zhu, Hao Wen, Xia Xue, Zhong-xian Tian, Hong Sun, Pei-chao Li, Xiao-gang Zhao
Acta Pharmacologica Sinica.2024; 45(5): 1060.     CrossRef
Folic acid receptor conjugated mesoporous CaCO3 nanoformulation for the therapeutic potential against lung carcinoma
Prakashkumar Nallasamy, Suganthy Natarajan
Journal of Drug Delivery Science and Technology.2024; 92: 105392.     CrossRef
Cibler le splicéosome : une nouvelle stratégie thérapeutique pour contrecarrer la résistance à la chimiothérapie dans les cancers du poumon ?
A. Shreim, S. Gazzeri, B. Eymin
Revue des Maladies Respiratoires.2024; 41(4): 294.     CrossRef
Trilobolide-6-O-isobutyrate from Sphagneticola trilobata acts by inducing oxidative stress, metabolic changes and apoptosis-like processes by caspase 3/7 activation of human lung cancer cell lines
Virginia Marcia Concato-Lopes, Manoela Daiele Gonçalves-Lens, Fernanda Tomiotto-Pellissier, Mariana Barbosa Detoni, Ellen Mayara Souza Cruz, Bruna Taciane da Silva Bortoleti, Amanda Cristina Machado Carloto, Ana Carolina Jacob Rodrigues, Taylon Felipe Sil
Phytomedicine.2024; 128: 155536.     CrossRef
Delivery of miR-29a improves the permeability of cisplatin by downregulating collagen I expression
Zhongyu Qin, Jin Ma, Xu Chu, Taozhen Guo, Pengcheng Feng, Ming Wang
Biochemical and Biophysical Research Communications.2024; 710: 149884.     CrossRef
Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization
Haoran Wang, Yuping Chen, Xinshu Wang, Binhao Huang, Juntao Xie, Hui Yin, Jie Yang, Jinhuan Wu, Jian Yuan, Jie Zhang
Clinical Cancer Research.2024; 30(8): 1607.     CrossRef
Exploring Synergistic Interactions between Natural Compounds and Conventional Chemotherapeutic Drugs in Preclinical Models of Lung Cancer
Mihaela Boța, Lavinia Vlaia, Alex-Robert Jîjie, Iasmina Marcovici, Flavia Crişan, Cristian Oancea, Cristina Adriana Dehelean, Tudor Mateescu, Elena-Alina Moacă
Pharmaceuticals.2024; 17(5): 598.     CrossRef
Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent‐loaded nanoparticles
Taufique Siddiquee, Navya Ajitkumar Bhaskaran, Khushali Nathani, Sujata P. Sawarkar
Phytotherapy Research.2024;[Epub]     CrossRef
A review on non-small cell lung cancer
Sunil Kumar Verma, Minakshi Pandey, Renu Khare, Devendra Singh
Vacunas (English Edition).2024; 25(2): 239.     CrossRef
New Targeted Therapy for Non-Small Cell Lung Cancer
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Tuberculosis and Respiratory Diseases.2023; 86(1): 1.     CrossRef
Recent Advances in Lung Cancer Therapy Based on Nanomaterials: A Review
Leila Gholami, Jalil Rouhani Ivari, Niloofar Khandan Nasab, Reza Kazemi Oskuee, Thozhukat Sathyapalan, Amirhossein Sahebkar
Current Medicinal Chemistry.2023; 30(3): 335.     CrossRef
Pulmonary Surfactant-Based Paclitaxel-Loaded Nanovesicles for Inhalation Therapy of Lung Adenocarcinoma
Chanhee Oh, Ok Hwa Jeon, Junhee Han, Kyungsu Kim, Hyun Koo Kim, Ji-Ho Park
ACS Applied Nano Materials.2023; 6(5): 3693.     CrossRef
Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer
Ga-Ram Hwang, John G. Yuen, Andrew Fesler, Hannah Farley, John D. Haley, Jingfang Ju
Molecular Therapy - Oncolytics.2023; 28: 277.     CrossRef
Preparation, characterisation, and in vitro cancer‐suppression function of RNA nanoparticles carrying miR‐301b‐3p Inhibitor
Junjie Zhao, Niu Niu, Fan Yang, Haitao Liu, Weibo Qi
IET Nanobiotechnology.2023; 17(3): 224.     CrossRef
The effect of nursing intervention combined with PD-1 inhibitor on platelets, white blood cells, tumor markers and quality of life in patients with lung cancer
Jianna Liu, Aiju Wang, Xianzhong Zhang, Xinting You, Yanzheng Wang
Biotechnology and Genetic Engineering Reviews.2023; : 1.     CrossRef
Not all benzimidazole derivatives are microtubule destabilizing agents
In-ho Song, Su Jeong Park, Gyu Seong Yeom, Keum-soo Song, Taisun Kim, Satish Balasaheb Nimse
Biomedicine & Pharmacotherapy.2023; 164: 114977.     CrossRef
The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
Tingting Lu, Yufan Huang, Zhongjie Cai, Wangchun Lin, Xiaoxiao Chen, Ruijia Chen, Yingying Hu
Frontiers in Pharmacology.2023;[Epub]     CrossRef
Development of a Highly In Vivo Efficacious Dual Antitumor and Antiangiogenic Organoiridium Complex as a Potential Anti-Lung Cancer Agent
Shubhankar Gadre, Manikandan M, Gourav Chakraborty, Amey Rayrikar, Subhadeep Paul, Chinmoy Patra, Malay Patra
Journal of Medicinal Chemistry.2023; 66(19): 13481.     CrossRef
Methotrexate-conjugated zinc oxide nanoparticles exert a substantially improved cytotoxic effect on lung cancer cells by inducing apoptosis
Prakriti Mishra, Mohd Faizan Ali Ahmad, Lamya Ahmed Al-Keridis, Mohd Saeed, Nawaf Alshammari, Nadiyah M. Alabdallah, Rohit Kumar Tiwari, Afza Ahmad, Mahima Verma, Shireen Fatima, Irfan Ahmad Ansari
Frontiers in Pharmacology.2023;[Epub]     CrossRef
Single-cell mass cytometric analysis of peripheral immunity and multiplex plasma marker profiling of non-small cell lung cancer patients receiving PD-1 targeting immune checkpoint inhibitors in comparison with platinum-based chemotherapy
Patrícia Neuperger, Klára Szalontai, Nikolett Gémes, József Á. Balog, László Tiszlavicz, József Furák, György Lázár, László G. Puskás, Gábor J. Szebeni
Frontiers in Immunology.2023;[Epub]     CrossRef
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy
Faizan Haider Khan, Basharat Ahmad Bhat, Bashir Ahmad Sheikh, Lubna Tariq, Roshan Padmanabhan, Jay Prakash Verma, Amritesh Chandra Shukla, Afshin Dowlati, Ata Abbas
Seminars in Cancer Biology.2022; 86: 732.     CrossRef
Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of non‐small cell lung cancer
Lin Zhu, Rui Chen, Qianyu Yang, Hongxia Liu, Qingshan Zheng, Lujin Li
Journal of Clinical Pharmacy and Therapeutics.2022; 47(7): 986.     CrossRef
Photodynamic Therapy in Combination with Doxorubicin Is Superior to Monotherapy for the Treatment of Lung Cancer
Joseph C. Cacaccio, Farukh A. Durrani, Joseph R. Missert, Ravindra K. Pandey
Biomedicines.2022; 10(4): 857.     CrossRef
EZH2 regulates a SETDB1/ΔNp63α axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma
Seamus Balinth, Matthew L. Fisher, Yon Hwangbo, Caizhi Wu, Carlos Ballon, Xueqin Sun, Alea A. Mills
Oncogene.2022; 41(35): 4130.     CrossRef
Risk factors of inability to live independently in the course of lung cancer
Marek Tradecki, Jolanta Ziółkowska, Roma Roemer-Ślimak, Grzegorz Mazur, Aleksandra Butrym
Postępy Higieny i Medycyny Doświadczalnej.2022; 76(1): 402.     CrossRef
Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review)
Miguel Ortega, Fátima Navarro, Leonel Pekarek, Oscar Fraile‑Martínez, Cielo García‑Montero, Miguel Saez, Monica Arroyo, Jorge Monserrat, Melchor Alvarez‑Mon
International Journal of Oncology.2022;[Epub]     CrossRef
Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1
Jianjun Li, Yaqi Kou, Xiaohan Zhang, Xuechun Xiao, Yang Ou, Lixia Cao, Min Guo, Chunchun Qi, Zhaoyang Wang, Yuxin Liu, Qiuying Shuai, Hang Wang, Shuang Yang
Discover Oncology.2022;[Epub]     CrossRef
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non–small cell lung cancer
Anastasios Dimou, Cecile Nasarre, Yuri K. Peterson, Rose Pagano, Monika Gooz, Patrick Nasarre, Harry A. Drabkin, Kent E. Armeson, Barry C. Gibney, Robert M. Gemmill, Chadrick E. Denlinger
The Journal of Thoracic and Cardiovascular Surgery.2021; 162(2): 463.     CrossRef
2D Nanomaterial, Ti3C2 MXene-Based Sensor to Guide Lung Cancer Therapy and Management
Mahek Sadiq, Lizhi Pang, Michael Johnson, Venkatachalem Sathish, Qifeng Zhang, Danling Wang
Biosensors.2021; 11(2): 40.     CrossRef
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)
Seung Hyeun Lee, Cheol‐Kyu Park, Sung Yong Lee, Chang‐Min Choi
Thoracic Cancer.2021; 12(8): 1264.     CrossRef
Mechanisms of resistance to chemotherapy in non-small cell lung cancer
Hye-Young Min, Ho-Young Lee
Archives of Pharmacal Research.2021; 44(2): 146.     CrossRef
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer
Chenyang Zhao, Fengli Wang, Jihan Huang, Yinghua Lv, Fang Yin, Hongxia Liu, Qingshan Zheng, Lujin Li
European Journal of Clinical Pharmacology.2021; 77(5): 685.     CrossRef
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
Mark R. Middleton, Emma Dean, Thomas R. J. Evans, Geoffrey I. Shapiro, John Pollard, Bart S. Hendriks, Martin Falk, Ivan Diaz-Padilla, Ruth Plummer
British Journal of Cancer.2021; 125(4): 510.     CrossRef
Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products
Iksen, Sutthaorn Pothongsrisit, Varisa Pongrakhananon
Molecules.2021; 26(13): 4100.     CrossRef
The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
Tongwei Zhao, Guangyun Mao, Ming Chen, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1.     CrossRef
Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
Boksoon Chang, In Kyung Hwang, Seung Hyeun Lee
OncoTargets and Therapy.2021; Volume 14: 5097.     CrossRef
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Roberto Ruiz-Cordero, Walter Patrick Devine
Surgical Pathology Clinics.2020; 13(1): 17.     CrossRef
Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma
Youwei Zhang, He Du, Yang Li, Yuan Yuan, Bi Chen, Sanyuan Sun
Cancer Science.2020; 111(2): 637.     CrossRef
Metal element alteration in the lung by cisplatin and CV247 administration
Klára Szentmihályi, Anna Blázovics, Zoltán May, Miklós Mohai, Krisztina Süle, Mihály Albert, Gábor Szénási, Andor Sebestény, Csaba Máthé
Biomedicine & Pharmacotherapy.2020; 128: 110307.     CrossRef
Current Status of Immunotherapy for Lung Cancer and Future Perspectives
Ho Cheol Kim, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2020; 83(1): 14.     CrossRef
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer
Elham Hatami, Prashanth K.B. Nagesh, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
European Journal of Pharmacology.2020; 888: 173486.     CrossRef

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression

Won Gun Kwack, So Youn Shin, Seung Hyeun Lee
OncoTargets and Therapy.2020; Volume 13: 8901.     CrossRef
IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma
Lorenzo Islas-Vazquez, Dolores Aguilar-Cazares, Miriam Galicia-Velasco, Uriel Rumbo-Nava, Manuel Meneses-Flores, Cesar Luna-Rivero, Jose Sullivan Lopez-Gonzalez
Biology.2020; 9(11): 376.     CrossRef
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
Ramon Andrade de Mello, Nathália Moisés Neves, Hakaru Tadokoro, Giovanna Araújo Amaral, Pedro Castelo-Branco, Victor André de Almeida Zia
Journal of Clinical Medicine.2020; 9(11): 3543.     CrossRef
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway
Jiafei Liu, Like Qu, Lin Meng, Chengchao Shou
Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef